Treatment Information for VIDAZA
Important Safety Information
Understanding Side Effects
Other Considerations with VIDAZA
FAQs about VIDAZA
Patient Guide
Important Safety Information
Prescribing Information
Register For Updates

How does VIDAZA treat MDS?

When you have MDS, your bone marrow usually makes fewer healthy blood cells. The blood cells it does make don't always work as they should. VIDAZA is the first drug approved by the US Food and Drug Administration (FDA) for the treatment of all FAB subtypes of MDS. VIDAZA may be able to help your bone marrow make healthy blood cells again.

Bone Marrow

There are different ways of classifying MDS. One system (International Prognostic Scoring System or IPSS) uses cell type and blood counts of patients with MDS to predict the course of their disease. This system separates patients into lower-risk and higher-risk categories. This helps doctors determine a treatment plan for each patient.

Another system (French-American-British or FAB) divides MDS into 5 groups called subtypes. VIDAZA is used to treat patients with all 5 FAB subtypes. Your doctor can explain which subtype of MDS you have.

The 5 FAB MDS subtypes that VIDAZA treats are:

*Refractory anemia = low blood cell amounts that do not respond to supportive care.
Excess blasts = increased number of immature blood cells in the bone marrow.

Why was VIDAZA prescribed?

Your doctor may have prescribed VIDAZA to help reduce your need for RBC transfusions. VIDAZA may also help your bone marrow make healthy WBCs and platelets. Your doctor may prescribe VIDAZA for as long as you continue to benefit from it and side effects don't require that you stop treatment. Always follow your doctor's recommendations about continuing your treatment plan.

Please see Important Safety Information and full Prescribing Information.